US & China Asthma and COPD Drugs Market

1
Asthma is a disease characterized by recurrent
attacks of coughing, chest-tightening,
breathlessness, and wheezing as the airways
narrow and swell that vary in severity and
frequency. COPD is a disease of the lungs
characterized by obstruction to airflow that
interferes with normal breathing. .
US China Asthma and COPD Drugs Market
2
U.S. and China Asthma and COPD Drugs Market
Snapshot

• The U.S. and China market for asthma and chronic
  obstructive pulmonary disease (COPD) drugs is
  expected to exhibit growth at a steady pace in
  the next few years. Factors such as a significant
  rise prevalence of COPD and asthma in these two
  countries, advancements in diagnostic methods,
  and rising awareness among patients regarding the
  available treatment methods are considered key to
  the overall growth of the market over the period
  20162024.
• The market is expected to exhibit growth at a
  moderate pace in the first few years of the
  forecast period, chiefly owing to the patent
  expiries of leading drugs and the subsequent
  price erosion. However, the market is expected to
  witness new drug candidates by 2020, which will
  help the market tread along a better growth path
  in the forthcoming years.
• Transparency Market Research estimates that the
  market will exhibit a 4.1 CAGR from 2016 through
  2024, rising to a valuation of US18.7 bn by 2024
  from US13.0 bn in 2015.

3
(No Transcript)
4
Table of Content
Sr. No. Content
Chapter1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary
Chapter 4 Market Overview
Chapter 5 U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Drug Class
Chapter 6 U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Indication
Chapter 7 U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Region
Chapter 8 U.S. Asthma and COPD Drugs Market Analysis and Forecast
Chapter 9 China Asthma and COPD Drugs Market Analysis and Forecast
Chapter 10 Competition Landscape





Access Full TOC
5
Report Highlights

• Transparency Market Research estimates that the
  US China Asthma and COPD Drugs Market will
  exhibit a 4.1 CAGR from 2016 through 2024,
  rising to a valuation of US18.7 bn by 2024 from
  US13.0 bn in 2015

• Some of the leading vendors presently operating
  in the U.S. and China asthma and COPD drugs
  market profiled in the report are Boehringer
  Ingelheim, GlaxoSmithKline plc, Merck and Co.,
  Inc., Novartis AG, AstraZeneca plc, and F.
  Hoffmann-La Roche.

Request Sample of Report
6
About Us

• Transparency Market Research (TMR) is a market
  intelligence company, providing North America
  business information reports and services. Our
  exclusive blend of quantitative forecasting and
  trends analysis provides forward-looking insight
  for thousands of decision-makers. We have an
  experienced team of Analysts, Researchers, and
  Consultants, who use proprietary data sources and
  various tools and techniques to gather and
  analyze information. Our business offerings
  represent the latest and the most reliable informa
  tion indispensable for businesses to sustain a
  competitive edge.
• Each TMR Syndicated Research report covers a
  different sectorsuch as pharmaceuticals,
  chemical, energy, food beverages,
  semiconductors, med-devices, consumer goods, and
  technology. These reports provide in-depth
  analysis and deep segmentation to possible micro
  levels. With a wider scope and stratified
  research methodology, our syndicated reports
  strive to serve clients and satisfy their overall
  research requirement.

7
(No Transcript)